Search results
Results from the WOW.Com Content Network
Histopathology of a ballooning hepatocyte.png, H&E stain. Ballooning degeneration centre-left and centre-right. H&E stain. A Councilman body can also be seen in the upper-right of the section. In histo pathology, ballooning degeneration, formally ballooning degeneration of hepatocytes, is a form of liver parenchymal cell (i.e. hepatocyte) death.
A hepatocyte is a cell of the main parenchymal tissue of the liver. Hepatocytes make up 80% of the liver's mass. These cells are involved in: Protein synthesis;
In histo pathology, feathery degeneration, formally feathery degeneration of hepatocytes, is a form of liver parenchymal cell (i.e. hepatocyte) death associated with cholestasis. [1] Cells undergoing this form of cell death have a flocculant appearing cytoplasm, [2] and are larger than normal hepatocytes.
Hepatocytes constitute about 80% of the cell population of the liver, with the other 20% being occupied by Kupffer cells, hepatic stellate cells, endothelial cells and mesothelial cells, which are not exactly characteristic of the liver, but are present in the liver samples. [2] Histologically speaking, hepatocytes have specific characteristics.
Cirrhosis and chronic liver disease were the tenth leading cause of death for men and the twelfth for women in the United States in 2001, killing about 27,000 people each year. [ 157 ] The cause of cirrhosis can vary; alcohol and non-alcoholic fatty liver disease are main causes in western and industrialized countries, whereas viral hepatitis ...
Death occurs in 20–40% of those affected with Reye syndrome, and about a third of those who survive are left with a significant degree of brain damage. [2] [3] The cause of Reye syndrome is unknown. [2] It usually begins shortly after recovery from a viral infection, such as influenza or chickenpox. [1]
Ischemic hepatitis, also known as shock liver, is a condition defined as an acute liver injury caused by insufficient blood flow (and consequently insufficient oxygen delivery) to the liver. [5]
Cabozantinib, which is an inhibitor of multiple tyrosine kinases including VEGFR, hepatocyte growth factor receptor (MET) and AXL and ramucirumab, an antibody directed against VEGF receptor 2, are second line therapies which have been shown to reduce the risk of death compared to placebo. [6] [79] [80]